Aptar Pharma will unveil Prohaler®, the smart DPI for optimal patient compliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

 

Aptar Pharma will unveil Prohaler®, the smart DPI for optimal patient compliance

During the next edition of CPHI/ICSE Europe tradeshow which be held on October 7th to October 9th, in Paris Villepinte, Aptar Pharma will introduce Prohaler®, the smart DPI for optimal patient.  

The Prohaler® DPI has been developed with a patient-based design approach which makes it intuitive and simple to use by all asthma and COPD patients.

Prohaler® features a novel powder dispersion technology enabling consistent lung deposition even while operating at relatively low patient inhalation flow rates. The results of a recent research showed that Prohaler® has excellent ergonomics, providing intuitive and constant handling characteristics. It is easy to use, with only 3 simple steps needed: open the device, inhale and close it; inhaling triggers the release of a full dose of medication. And a dose counter reminds the patient how many doses are left in the device.

Prohaler® incorporates visual and audible feed-back systems to facilitate ease-of-use and patient compliance.

Prohaler® also has a unique patient safety feature to avoid any risk of double-dosing and wasted doses. And the drug product is protected inside individual blisters which are only opened upon inhalation by the patient, providing optimal powder protection.

For more information on Prohaler®, please visit our booth #2F35, hall 2, or our website: www.aptar.com/pharma

Contact details:
Aptar Pharma
36-36 Rue de la Princesse
78431 Louveciennes Cedex - France
Telephone number: + 33 (0)1 39 17 20 20
Fax number: + 33 (0)1 39 58 12 98
Email: info.pharma@aptar.com
www.aptar.com/pharma

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
FindPharma Custom Search

Click here